Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases.
To contact Derek email him directly: derekb.lowe@gmail.com
Twitter: Dereklowe
Thanks to Lisa Jarvis at C&E News, here's a chart (PDF) of the 39 drugs approved last year by the FDA. Last year was a good year, by almost any measure. The question as we go on will be whether this was a one-time spike, or the start of a long-awaited turnaround. If the latter, I think it will be as much of a regulatory phenomenon as a scientific one (faster reviews, etc.)
1. nitrosoniumn on February 11, 2013 1:38 PM writes...
did you work on early stage discovery/development of Kalydeco?
Permalink to Comment2. darwinsdog on February 12, 2013 3:06 PM writes...
Among biologics few MAbs (two)
Permalink to Comment3. R&D Chemist on February 25, 2013 1:10 PM writes...
Need more critical thinking on how to approach proof of concept and clinical trails:
http://www.reuters.com/article/2013/02/25/us-cancer-drugs-idUSBRE91O07K20130225
Permalink to Comment